{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T12:12:40Z","timestamp":1761912760416,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019632","name":"Agence R\u00e9gionale de Sant\u00e9 Provence-Alpes-C\u00f4te d'Azur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.therap.2025.02.006","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T11:10:08Z","timestamp":1740741008000},"page":"507-518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pr\u00e9vention du m\u00e9susage et du risque des surdoses d\u2019opio\u00efdes et diffusion de naloxone\u00a0: \u00e9tat des lieux des pratiques, besoins et perspectives aupr\u00e8s des pharmaciens d\u2019officine"],"prefix":"10.1016","volume":"80","author":[{"given":"Armelle","family":"Chan Soc Foh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Mezaache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Turlure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Fredon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Pichon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Peillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joelle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-5625","authenticated-orcid":false,"given":"Elisabeth","family":"Frauger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2025.02.006_bib0225","unstructured":"L\u2019Assurance maladie. Rapport au minist\u00e8re charg\u00e9 de la S\u00e9curit\u00e9 sociale et au Parlement sur l\u2019\u00e9volution des charges et des produits de l\u2019Assurance Maladie au titre de 2025. 2024. https:\/\/www.assurance-maladie.ameli.fr\/sites\/default\/files\/2024-07_rapport-propositions-pour-2025_assurance-maladie.pdf [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025 (425\u00a0pp.)]."},{"key":"10.1016\/j.therap.2025.02.006_bib0230","unstructured":"CDC. Overdose prevention. 2024. Understanding the opioid overdose epidemic. 2024. https:\/\/www.cdc.gov\/overdose-prevention\/about\/understanding-the-opioid-overdose-epidemic.html [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0235","unstructured":"World Health Organization. Surdose d\u2019opio\u00efdes. 2023. https:\/\/www.who.int\/fr\/news-room\/fact-sheets\/detail\/opioid-overdose [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0240","unstructured":"R\u00e9seau fran\u00e7ais d\u2019addictovigilance. DRAMES. 2024. https:\/\/addictovigilance.fr\/programmes-dobservation\/drames\/ [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0245","unstructured":"R\u00e9seau fran\u00e7ais d\u2019addictovigilance. DTA. 2024. https:\/\/addictovigilance.fr\/programmes-dobservation\/dta\/ [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0250","unstructured":"Nations unies. Bo\u00eete \u00e0 outils de l\u2019ONU sur les drogues synth\u00e9tiques. Opioid overdose. 2024. https:\/\/syntheticdrugs.unodc.org\/syntheticdrugs\/fr\/treatment\/opioidoverdose\/index.html [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0255","unstructured":"Minist\u00e8re de la sant\u00e9 et de la pr\u00e9vention. Pr\u00e9venir et agir face aux surdoses d\u2019opio\u00efdes\u00a0: feuille de route 2019\u20132022. 2024. https:\/\/sante.gouv.fr\/prevention-en-sante\/addictions\/article\/prevenir-et-agir-face-aux-surdoses-d-opioides-feuille-de-route-2019-2022 [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0260","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Bon usage des m\u00e9dicaments opio\u00efdes\u00a0: antalgie, pr\u00e9vention et prise en charge du trouble de l\u2019usage et des surdoses. 2022. https:\/\/www.has-sante.fr\/jcms\/p_3215131\/fr\/bon-usage-des-medicaments-opioides-antalgie-prevention-et-prise-en-charge-du-trouble-de-l-usage-et-des-surdoses [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0265","unstructured":"Cespharm \u2013\u00a0r\u00e9duction des risques et des dommages dans le champ de l\u2019addiction aux opio\u00efdes\u00a0\u2013 document professionnel. 2024. https:\/\/www.cespharm.fr\/prevention-sante\/catalogue\/Reduction-des-Risques-et-des-Dommages-dans-le-champ-de-l-addiction-aux-opioides-document-professionnel [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0395","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s11606-022-07643-w","article-title":"Time for pharmacy co-dispensing of naloxone with prescribed opioids?","volume":"37","author":"Wunderlich","year":"2022","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.therap.2025.02.006_bib0270","unstructured":"R\u00e9seau fran\u00e7ais d\u2019addictovigilance. OPPIDUM. 2024. https:\/\/addictovigilance.fr\/programmes-dobservation\/oppidum\/."},{"key":"10.1016\/j.therap.2025.02.006_bib0275","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.therap.2016.05.001","article-title":"Les 25\u00a0ans des centres d\u2019\u00e9valuation et d\u2019information sur la pharmacod\u00e9pendance-addictovigilance","volume":"71","author":"Micallef","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.02.006_bib0280","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.therap.2019.09.005","article-title":"Safety signal detection by the French Addictovigilance Network: Innovative methods of investigation, examples and usefulness for public health","volume":"74","author":"Micallef","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.02.006_bib0285","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.therap.2023.03.008","article-title":"Pr\u00e9vention des surdoses opio\u00efdes et diffusion de naloxone (programme POP)\u00a0: r\u00e9sultats d\u2019un \u00e9tat des lieux r\u00e9alis\u00e9 aupr\u00e8s des structures d\u2019addictologie","volume":"78","author":"Mezaache","year":"2023","journal-title":"Therapie"},{"issue":"544, Supplement","key":"10.1016\/j.therap.2025.02.006_bib0290","first-page":"17","article-title":"Addiction avec opiac\u00e9s\u00a0: le r\u00f4le du pharmacien","volume":"54","author":"Chevalier","year":"2015","journal-title":"Actual Pharm"},{"key":"10.1016\/j.therap.2025.02.006_bib0295","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.therap.2018.03.003","article-title":"Pratique de l\u2019ATU de cohorte de la naloxone intranasale (Nalscue\u00ae)\u00a0: mise en place dans un CSAPA parisien","volume":"73","author":"Barr\u00e9","year":"2018","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.02.006_bib0300","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.therap.2019.01.005","article-title":"Retour d\u2019exp\u00e9rience de deux CSAPA et enqu\u00eate nationale sur la naloxone intranasale (Nalscue\u00ae) dans la pr\u00e9vention des overdoses aux opio\u00efdes","volume":"74","author":"Lenglard","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2025.02.006_bib0305","unstructured":"Direction g\u00e9n\u00e9rale de la sant\u00e9. C\u00e9line M. Minist\u00e8re du Travail, de la Sant\u00e9 et des Solidarit\u00e9s. 2024. Surdoses (overdose) d\u2019opio\u00efdes\u00a0: la naloxone est utilisable par tous et peut sauver la vie. 2023. https:\/\/sante.gouv.fr\/prevention-en-sante\/addictions\/article\/surdoses-overdose-d-opioides-la-naloxone-est-utilisable-par-tous-et-peut-sauver [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0310","unstructured":"Equip\u2019addict. D\u00e9veloppement harmonis\u00e9 du dispositif des microstructures m\u00e9dicales addictions. 2023. https:\/\/sante.gouv.fr\/IMG\/pdf\/equip_addict_rapport_final_hcl-vf.pdf [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025 (171\u00a0pp.)]."},{"key":"10.1016\/j.therap.2025.02.006_bib0315","unstructured":"Conseil national de l\u2019Ordre des m\u00e9decins, Conseil national de l\u2019Ordre des pharmaciens. Recommandations des Conseils Nationaux de l\u2019Ordre des M\u00e9decins et des Pharmaciens \u00e0 propos de la prescription et de la dispensation des traitements de substitution aux opiac\u00e9s. 2024. https:\/\/www.conseil-national.medecin.fr\/sites\/default\/files\/external-package\/rapport\/1933uk4\/recommandations_cnom_cnop.pdf [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025 (27\u00a0pp.)]."},{"key":"10.1016\/j.therap.2025.02.006_bib0320","unstructured":"Bouderbala B, Monge J, Reyne B. Diffusion de la naloxone en France. 2019. https:\/\/www.addictaide.fr\/wp-content\/uploads\/2019\/09\/Diffusion-de-la-naloxone.pdf.[Consult\u00e9 le 24\u00a0f\u00e9vrier 2025 (12\u00a0pp.)]."},{"key":"10.1016\/j.therap.2025.02.006_bib0325","first-page":"23","article-title":"Approche globale du traitement de substitution aux opio\u00efdes","volume":"56","author":"Chevalier","year":"2017","journal-title":"Actual Pharm"},{"key":"10.1016\/j.therap.2025.02.006_bib0330","first-page":"31","article-title":"R\u00f4le du pharmacien aupr\u00e8s des patients opiod\u00e9pendants","volume":"56","author":"Pansiot","year":"2017","journal-title":"Actual Pharm"},{"key":"10.1016\/j.therap.2025.02.006_bib0335","first-page":"33","article-title":"Pharmacien et addictions, un engagement \u00e9vident","volume":"61","author":"Bonnet","year":"2022","journal-title":"Actual Pharm"},{"key":"10.1016\/j.therap.2025.02.006_bib0340","first-page":"20","article-title":"Les m\u00e9dicaments \u00e0 risque d\u2019usage d\u00e9tourn\u00e9 et de d\u00e9pendance","volume":"63","author":"Gauthier","year":"2024","journal-title":"Actual Pharm"},{"key":"10.1016\/j.therap.2025.02.006_bib0345","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.therap.2024.07.001","article-title":"Physicians, pharmacists and take-home naloxone: what practices? The SINFONI study","volume":"79","author":"Duval","year":"2024","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2025.02.006_bib0350","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.therap.2022.10.048","article-title":"Urgence naloxone\u00a0: regards crois\u00e9s de m\u00e9decins, pharmaciens et patients en Pays de la Loire","volume":"77","author":"Aquizerate","year":"2022","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2025.02.006_bib0355","unstructured":"ANSM. Actualit\u00e9\u00a0\u2013\u00a0les autorit\u00e9s de sant\u00e9 alertent sur la circulation croissante d\u2019opio\u00efdes de synth\u00e8se, dont une nouvelle classe particuli\u00e8rement dangereuse, d\u00e9sormais inscrite sur la liste des stup\u00e9fiants. 2024. https:\/\/ansm.sante.fr\/actualites\/les-autorites-de-sante-alertent-sur-la-circulation-croissante-dopioides-de-synthese-dont-une-nouvelle-classe-particulierement-dangereuse-desormais-inscrite-sur-la-liste-des-stupefiants [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0360","unstructured":"ANSM. Actualit\u00e9\u00a0\u2013\u00a0l\u2019ANSM rappelle les risques de la m\u00e9thadone et l\u2019importance de disposer de la naloxone. 2020. https:\/\/ansm.sante.fr\/actualites\/lansm-rappelle-les-risques-de-la-methadone-et-limportance-de-disposer-de-la-naloxone [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0365","doi-asserted-by":"crossref","unstructured":"ANSM. Actualit\u00e9\u00a0\u2013\u00a0tramadol\u00a0: moins de comprim\u00e9s dans les bo\u00eetes pour un meilleur usage. 2024. https:\/\/ansm.sante.fr\/actualites\/tramadol-moins-de-comprimes-dans-les-boites-pour-un-meilleur-usage [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025].","DOI":"10.1016\/S1773-035X(24)00243-0"},{"key":"10.1016\/j.therap.2025.02.006_bib0370","unstructured":"ANSM. Actualit\u00e9\u00a0\u2013\u00a0tramadol et cod\u00e9ine devront \u00eatre prescrits sur une ordonnance s\u00e9curis\u00e9e d\u00e8s le 1er\u00a0d\u00e9cembre. 2024. https:\/\/ansm.sante.fr\/actualites\/tramadol-et-codeine-devront-etre-prescrits-sur-une-ordonnance-securisee-des-le-1er-decembre [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0375","first-page":"843","article-title":"Overdose aux opio\u00efdes\u00a0: pr\u00e9sentation clinique et place de la naloxone","volume":"200","author":"M\u00e9garbane","year":"2016","journal-title":"Bull Acad Nat Med"},{"key":"10.1016\/j.therap.2025.02.006_bib0380","doi-asserted-by":"crossref","first-page":"e2427236","DOI":"10.1001\/jamanetworkopen.2024.27236","article-title":"Pharmacy naloxone standing order and community opioid fatality rates over time","volume":"7","author":"Xuan","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.therap.2025.02.006_bib0385","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamainternmed.2019.0272","article-title":"Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose","volume":"179","author":"Abouk","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.therap.2025.02.006_bib0390","unstructured":"FDA. Commissioner of the FDA. FDA Approves first over-the-counter naloxone nasal spray. 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-over-counter-naloxone-nasal-spray [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0400","doi-asserted-by":"crossref","first-page":"E1312","DOI":"10.1503\/cmaj.230128-f","article-title":"Document d\u2019orientation sur la distribution et l\u2019utilisation de trousses de naloxone \u00e0 emporter par les intervenants et intervenantes communautaires en cas de surdose au Canada","volume":"195","author":"Ferguson","year":"2023","journal-title":"CMAJ"},{"key":"10.1016\/j.therap.2025.02.006_bib0405","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/add.15324","article-title":"Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: a population-based time\u00a0\u2013\u00a0series analysis","volume":"116","author":"Antoniou","year":"2021","journal-title":"Addiction (Abingdon Engl)"},{"key":"10.1016\/j.therap.2025.02.006_bib0410","doi-asserted-by":"crossref","first-page":"103146","DOI":"10.1016\/j.drugpo.2021.103146","article-title":"A qualitative study of a publicly funded pharmacy-dispensed naloxone program","volume":"92","author":"Antoniou","year":"2021","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.therap.2025.02.006_bib0415","unstructured":"Canada S. Naloxone. 2017. https:\/\/www.canada.ca\/fr\/sante-canada\/services\/opioides\/naloxone.html [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0420","unstructured":"NARCAN\u00ae (chlorhydrate de naloxone) VAPORISATEUR NASAL 4\u00a0mg. Le vaporisateur nasal NARCAN\u00ae. 2024. https:\/\/narcannasalspray.ca\/fr-CA\/ [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0425","unstructured":"Canada S. \u00c0 propos de la Loi sur les bons samaritains secourant les victimes de surdose. 2017. https:\/\/www.canada.ca\/fr\/sante-canada\/services\/opioides\/apropos-loi-bons-samaritains-secourant-victimes-surdose.html [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0430","unstructured":"Legifrance. Arr\u00eat\u00e9 du 5\u00a0juillet 2024\u00a0portant approbation de l\u2019avenant no\u00a01\u00a0\u00e0 la convention nationale du 9\u00a0mars 2022\u00a0organisant les rapports entres les pharmaciens titulaires d\u2019officine et l\u2019assurance maladie. 2024. https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000049892219 [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0435","unstructured":"Respadd. Pharmaciens et addictions\u00a0\u2013\u00a0RESPADD. 2019. https:\/\/www.respadd.org\/pharmaciens-et-addictions\/ [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."},{"key":"10.1016\/j.therap.2025.02.006_bib0220","unstructured":"Cespharm\u00a0\u2013\u00a0missions. 2019. https:\/\/www.cespharm.fr\/prevention-sante\/cespharm\/Missions [Consult\u00e9 le 24\u00a0f\u00e9vrier 2025]."}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725000344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725000344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T12:08:31Z","timestamp":1761912511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595725000344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0040595725000344"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2025.02.006","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pr\u00e9vention du m\u00e9susage et du risque des surdoses d\u2019opio\u00efdes et diffusion de naloxone\u00a0: \u00e9tat des lieux des pratiques, besoins et perspectives aupr\u00e8s des pharmaciens d\u2019officine","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2025.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}